Press release content from Business Wire. The AP news staff was not involved in its creation.
NANOBIOTIX 2020 Q4 and Annual Revenues
February 26, 2021 GMT
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the “
Company ”), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020.
ADVERTISEMENT
K€
Full Year and Fourth Quarter 2020 Financial Results
Nanobiotix generated annual revenue of approximately €50K, driven primarily by the charging-back of costs incurred on behalf of PharmaEngine in connection with the Company’s license and collaboration agreement with PharmaEngine. The absence of revenues in the fourth quarter of 2020 is explained by the issuance of a credit note following an annual adjustment.
NANOBIOTIX 2020 Q4 and Annual Revenues
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
– Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 –
– Ended 2020 with $213.2 million in cash, cash equivalents and investments –
– Company to host conference call and webcast today at 8:00 AM ET –
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.
“2020 proved to be a year of important pipeline execution and corporate development at Jounce despite the challenges presented by the COVID-19 pandemic. As we enter 2021, we are strongly positioned to execute on our two proof of concept studies, INNATE
CAR-T Therapy: Syndrome Released by Cytokine
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.